Literature DB >> 32311513

Unintentional drug overdose: Is more frequent use of non-prescribed buprenorphine associated with lower risk of overdose?

Robert G Carlson1, Raminta Daniulaityte2, Sydney M Silverstein3, Ramzi W Nahhas4, Silvia S Martins5.   

Abstract

BACKGROUND: Unintentional drug overdoses have reached epidemic levels in the U.S. This study tests the hypothesis that people who have used non-prescribed buprenorphine more frequently in the past six months were less likely to experience a drug overdose during that same time period.
METHODS: Participants age 18 years or older with opioid use disorder who reported use of non-prescribed buprenorphine in the last six months were recruited from the Dayton, Ohio, area using a combination of targeted and modified respondent-driven sampling. Participants completed a structured interview, including six-month timeline follow-back, after informed consent. Logistic regression was used to test the association between (log-transformed) frequency of non-prescribed buprenorphine use and overdose in the previous six months, adjusted for confounding due to sex, homelessness, incarceration, substance use treatment, previous overdose, heroin/fentanyl injection, psychiatric comorbidity, and (log-transformed) frequencies of other (non-opioid) drug use.
RESULTS: Almost 89% of 356 participants were white, 50.3% were male, and 78.1% had high school or greater education. Over 27% (n = 98) reported experiencing an overdose in the past six months. After adjusting for confounding, greater frequency of non-prescribed buprenorphine use was significantly associated with lower risk of overdose (AOR = 0.81, 95% CI = 0.66, 0.98; p = .0286). Experiencing an overdose more than six months ago (AOR = 2.19, 95% CI = 1.24, 3.97); injection as the most common route of administration of heroin/fentanyl (AOR = 2.49, 95% CI = 1.36, 4.71); and frequency of methamphetamine use (AOR = 1.13, 95% CI = 1.02, 1.27) were strongly associated with increased risk of recent overdose in multivariable analysis. DISCUSSION: The findings support our hypothesis that higher frequency of non-prescribed buprenorphine use is associated with lower risk of drug overdose, a potential harm reduction consequence of diversion. Improving the availability of buprenorphine though standard substance use disorder treatment, primary care, and other innovative methods is urgently needed.
Copyright © 2020. Published by Elsevier B.V.

Entities:  

Keywords:  Buprenorphine diversion; Heroin; Non-pharmaceutical fentanyl; Unintentional drug overdose

Year:  2020        PMID: 32311513      PMCID: PMC9387534          DOI: 10.1016/j.drugpo.2020.102722

Source DB:  PubMed          Journal:  Int J Drug Policy        ISSN: 0955-3959


  111 in total

1.  Research electronic data capture (REDCap)--a metadata-driven methodology and workflow process for providing translational research informatics support.

Authors:  Paul A Harris; Robert Taylor; Robert Thielke; Jonathon Payne; Nathaniel Gonzalez; Jose G Conde
Journal:  J Biomed Inform       Date:  2008-09-30       Impact factor: 6.317

2.  Does take-home naloxone reduce non-fatal overdose?

Authors:  Trevor Bennett; Katy Holloway; Sheila M Bird
Journal:  Lancet       Date:  2014-01-11       Impact factor: 79.321

3.  "Everything is not right anymore": Buprenorphine experiences in an era of illicit fentanyl.

Authors:  Sydney M Silverstein; Raminta Daniulaityte; Silvia S Martins; Shannon C Miller; Robert G Carlson
Journal:  Int J Drug Policy       Date:  2019-09-25

Review 4.  Buprenorphine Therapy for Opioid Use Disorder.

Authors:  Roger Zoorob; Alicia Kowalchuk; Maria Mejia de Grubb
Journal:  Am Fam Physician       Date:  2018-03-01       Impact factor: 3.292

5.  Medication for Opioid Use Disorder After Nonfatal Opioid Overdose and Association With Mortality: A Cohort Study.

Authors:  Marc R Larochelle; Dana Bernson; Thomas Land; Thomas J Stopka; Na Wang; Ziming Xuan; Sarah M Bagley; Jane M Liebschutz; Alexander Y Walley
Journal:  Ann Intern Med       Date:  2018-06-19       Impact factor: 25.391

Review 6.  Buprenorphine use: the international experience.

Authors:  Maria Patrizia Carrieri; Leslie Amass; Gregory M Lucas; David Vlahov; Alex Wodak; George E Woody
Journal:  Clin Infect Dis       Date:  2006-12-15       Impact factor: 9.079

7.  Prior Experience with Non-Prescribed Buprenorphine: Role in Treatment Entry and Retention.

Authors:  Laura B Monico; Shannon Gwin Mitchell; Jan Gryczynski; Robert P Schwartz; Kevin E O'Grady; Yngvild K Olsen; Jerome H Jaffe
Journal:  J Subst Abuse Treat       Date:  2015-05-07

8.  Factors associated with non-fatal heroin overdose: assessing the effect of frequency and route of heroin administration.

Authors:  M Teresa Brugal; Gregorio Barrio; La Fuente Luis De; Enrique Regidor; Luis Royuela; Josep M Suelves
Journal:  Addiction       Date:  2002-03       Impact factor: 6.526

9.  Trends in fentanyl and fentanyl analogue-related overdose deaths - Montgomery County, Ohio, 2015-2017.

Authors:  Raminta Daniulaityte; Matthew P Juhascik; Kraig E Strayer; Ioana E Sizemore; Mussa Zatreh; Ramzi W Nahhas; Kent E Harshbarger; Heather M Antonides; Silvia S Martins; Robert G Carlson
Journal:  Drug Alcohol Depend       Date:  2019-03-18       Impact factor: 4.852

10.  'Diversion' of methadone or buprenorphine: 'harm' versus 'helping'.

Authors:  Ingrid Amalia Havnes; Thomas Clausen; Anne-Lise Middelthon
Journal:  Harm Reduct J       Date:  2013-10-16
View more
  18 in total

1.  Switching of opioid agonist treatment modality during imprisonment: A novel marker for increased support need during and following release from prison.

Authors:  Michael Curtis; Justin Berk; Sarah Larney; Josiah D Rich; Mark Stoové
Journal:  Int J Drug Policy       Date:  2022-01-05

2.  On my own terms: Motivations for self-treating opioid-use disorder with non-prescribed buprenorphine.

Authors:  Sydney M Silverstein; Raminta Daniulaityte; Shannon C Miller; Silvia S Martins; Robert G Carlson
Journal:  Drug Alcohol Depend       Date:  2020-03-16       Impact factor: 4.492

3.  Putting the Horse Before the Unicorn: A Safe Supply Strategy Should Begin With Partial Agonists--A Commentary on Bonn et al. (2020).

Authors:  Brandon Del Pozo; Richard A Rawson
Journal:  J Stud Alcohol Drugs       Date:  2020-09       Impact factor: 2.582

4.  CommunityStat: A Public Health Intervention to Reduce Opioid Overdose Deaths in Burlington, Vermont, 2017-2020.

Authors:  Brandon Del Pozo
Journal:  Contemp Drug Probl       Date:  2021-10-06

5.  Availability and use of non-prescribed buprenorphine-naloxone in a Canadian setting, 2014-2020.

Authors:  Paxton Bach; Misha Bawa; Cameron Grant; M J Milloy; Kanna Hayashi
Journal:  Int J Drug Policy       Date:  2021-12-05

6.  The use of diverted pharmaceutical opioids is associated with reduced risk of fentanyl exposure among people using unregulated drugs in Vancouver, Canada.

Authors:  M Eugenia Socias; Cameron Grant; Kanna Hayashi; Geoff Bardwell; Mary Clare Kennedy; M-J Milloy; Thomas Kerr
Journal:  Drug Alcohol Depend       Date:  2021-09-25       Impact factor: 4.492

Review 7.  Methamphetamine use in the United States: epidemiological update and implications for prevention, treatment, and harm reduction.

Authors:  Christopher M Jones; Debra Houry; Beth Han; Grant Baldwin; Alana Vivolo-Kantor; Wilson M Compton
Journal:  Ann N Y Acad Sci       Date:  2021-09-24       Impact factor: 6.499

8.  "People need them or else they're going to take fentanyl and die": A qualitative study examining the 'problem' of prescription opioid diversion during an overdose epidemic.

Authors:  Geoff Bardwell; Will Small; Jennifer Lavalley; Ryan McNeil; Thomas Kerr
Journal:  Soc Sci Med       Date:  2021-05-03       Impact factor: 5.379

9.  Non-prescribed buprenorphine preceding treatment intake and clinical outcomes for opioid use disorder.

Authors:  Arthur Robin Williams; Christine M Mauro; Tianshu Feng; Amanda Wilson; Angelo Cruz; Mark Olfson; Stephen Crystal; Hillary Samples; Lisa Chiodo
Journal:  J Subst Abuse Treat       Date:  2022-03-21

10.  Negative affect-associated drug refusal self-efficacy, illicit opioid use, and medication use following short-term inpatient opioid withdrawal management.

Authors:  Jumi Hayaki; Micah T Conti; Genie L Bailey; Debra S Herman; Bradley J Anderson; Michael D Stein
Journal:  J Subst Abuse Treat       Date:  2021-01-27
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.